Literature DB >> 11606913

Treatment of psoriasis. Part 2. Systemic therapies.

M Lebwohl1, S Ali.   

Abstract

The array of systemic medications used in the treatment of psoriasis is rapidly expanding. In the United States, methotrexate, retinoids, and cyclosporine are the only systemic drugs approved by the Food and Drug Administration for the treatment of psoriasis. Monitoring and dosage recommendations for these medications are reviewed. Other drugs that are currently available include tacrolimus, mycophenolate mofetil, hydroxyurea, 6-thioguanine, and sulfasalazine. Experience with these drugs is summarized, and dosage and monitoring recommendations in published literature are presented. Combinations of different treatments are addressed and investigational therapies that are in development are reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606913     DOI: 10.1067/mjd.2001.117047

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

Review 1.  Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Authors:  Lotus Mallbris; Christopher T Ritchlin; Mona Ståhle
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

2.  Dermacase. Psoriasis.

Authors:  Irina Turchin; Stewart P Adams
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

3.  Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast.

Authors:  Layla Nabai; Ruhangiz T Kilani; Farzian Aminuddin; Yunyuan Li; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2015-08-23       Impact factor: 3.396

Review 4.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Cost-effectiveness of treatment with etanercept for psoriasis in Sweden.

Authors:  Christopher Knight; Josephine Mauskopf; Mats Ekelund; Amitabh Singh; Shiyi Yang; Robert Boggs
Journal:  Eur J Health Econ       Date:  2011-03-06

Review 6.  Psoriasis treatment: traditional therapy.

Authors:  M Lebwohl; P T Ting; J Y M Koo
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 7.  Ustekinumab: a new option in psoriasis therapy.

Authors:  Anna L Chien; James T Elder; Charles N Ellis
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

8.  The risk of stroke in patients with psoriasis.

Authors:  Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2009-05-21       Impact factor: 8.551

9.  Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.

Authors:  Nehal N Mehta; Rahat S Azfar; Daniel B Shin; Andrea L Neimann; Andrea B Troxel; Joel M Gelfand
Journal:  Eur Heart J       Date:  2009-12-27       Impact factor: 29.983

10.  Comparative therapeutic evaluation of different topicals and narrow band ultraviolet B therapy combined with systemic methotrexate in the treatment of palmoplantar psoriasis.

Authors:  Sunil K Gupta; K K Singh; Mohan Lalit
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.